Apr 03, 2026 | Trump's 100% Drug Tariffs Reshape Pharma; $25.5B M&A Spree

Trump signs 100% tariffs on imported drugs — but exemptions create a two-tier system reshaping competitive modeling. $25.5B in pharmaM&A in eight days as R&D pipeline shrinks for first time in 30 years. Lilly's Foundayo approved, oral obesity war heats up. ORIC crashes on dose selection.Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, drug tariffs, Section 232, Eli Lilly, Foundayo, orforglipron, Novo Nordisk, Wegovy, obesitydrugs, GLP-1, Biogen, Apellis, Centessa, Merck, Terns Pharma, ORIC Pharmaceuticals, rinzimetostat, CVR, contingent value rights, Pfizer, BioNTech,COVID vaccine, Gilead, HIV, Orca Bio, biopharma pipeline, pharmaceutical tariffs, reshoring, M&A, Blackstone, Ambrosia Biosciences, Lilly